ライフサイエンスコーパス: endocrine tumor

1 apillary mucinous neoplasms and 3 pancreatic endocrine tumors).

2 by a gastric carcinoid and not a pancreatic endocrine tumor.

3 sion in both human and mouse MEN1 pancreatic endocrine tumors.

4 ce are more susceptible to hematopoietic and endocrine tumors.

5 which dysregulation of cAMP signaling causes endocrine tumors.

6 7 of 8 (88%) cases of multifocal pancreatic endocrine tumors.

7 , which is mutated in heritable and sporadic endocrine tumors.

8 ntified as a promising marker for pancreatic endocrine tumors.

9 d by multiple endocrine and occasionally non-endocrine tumors.

10 wn of its expression in malignant pancreatic endocrine tumors.

11 carcimomas but are never found in pancreatic endocrine tumors.

12 astases in patients with sporadic pancreatic endocrine tumors.

13 h diabetes and for targeting menin-sensitive endocrine tumors.

14 Pheochromocytomas are rare endocrine tumors.

15 le in the development of sporadic pancreatic endocrine tumors.

16 , are thus successfully used in PET to image endocrine tumors.

17 advances have been made in the management of endocrine tumors.

18 se (AADC), the level of which is enhanced in endocrine tumors.

19 as, 13 other pancreatic cysts, 27 pancreatic endocrine tumors, 16 chronic pancreatitis, 9 ductal aden

20 c response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% am

21 ions were detected in 31 sporadic pancreatic endocrine tumors (34%).

22 sion patterns in normal pancreas, pancreatic endocrine tumors and acinar carcinomas to evaluate their

23 in approximately 40% of sporadic pancreatic endocrine tumors and hypothesize that MENIN is involved

24 cal carcinoma (ACC) is a rare but aggressive endocrine tumor, and the prognostic factors associated w

25 including 12 insulinomas, 28 nonfunctioning endocrine tumors, and four acinar carcinomas.

26 n pancreatic tumors including cystic tumors, endocrine tumors, and intraductal pancreatic mucinous ne

27 a number of nonendocrine tumors and in a few endocrine tumors, and its presence can correlate with tu

28 sias, including myxomas at various sites and endocrine tumors, and lentiginosis.

29 rized by parathyroid hyperplasia, pancreatic endocrine tumors, and pituitary adenomas.

30 ed by spotty skin pigmentation, myxomatosis, endocrine tumors, and schwannomas.

31 In some organs (eg, the lung), endocrine tumors are classified on the basis of mitotic

32 Endocrine tumors are often overlooked in medical oncolog

33 Pancreatic endocrine tumors are rare but have long held a fascinati

34 l carcinoid tumors and multifocal pancreatic endocrine tumors arise independently or whether they ori

35 Medullary thyroid carcinoma (MTC) is a rare endocrine tumor arising from the C-cells of the thyroid

36 tions in the MEN1 gene on chromosome 11, and endocrine tumors arising in these patients usually show

37 erior pituitary, and pancreatic and duodenal endocrine tumors as well as foregut carcinoids in affect

38 Many endocrine tumors can be caused by a variety of different

39 lated adult pancreatic islets and pancreatic endocrine tumor cell lines was determined to compile lis

40 ith (18)F-FDOPA PET/CT imaging in 2 academic endocrine tumor centers was conducted.

41 Endocrine tumors (ETs) of pancreas and duodenum occur sp

42 In contrast, RCAS-c-myc induced endocrine tumors exclusively, as determined by histology

43 of chromosome 1 may contribute to pancreatic endocrine tumor formation.

44 erior pituitary, and pancreatic and duodenal endocrine tumors in affected individuals.

45 ome characterized by development of multiple endocrine tumors in affected individuals.

46 Endocrine tumors in these patients result when the mutan

47 Characterization of colonic endocrine tumors in transgenic mice expressing simian vi

48 In gastrointestinal endocrine tumors including gastrinomas, little data are

49 ur understanding of the hereditary nature of endocrine tumors increases, the role of genetic counseli

50 nsus region they may play a role in sporadic endocrine tumors independent of the MEN1 gene or in othe

51 The molecular pathogenesis of pancreatic endocrine tumors is largely unknown.

52 unregulated secretion often associated with endocrine tumors may result, at least in part, from inef

53 cinoma, n = 17; sarcoma/melanoma, n = 4; and endocrine tumor, n = 6).

54 ved sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66).

55 Pancreatic endocrine tumors occur both sporadically and as part of

56 Endocrine tumors of the gastrointestinal tract produce a

57 LOH rates of parathyroid lesions (100%) and endocrine tumors of the pancreas (83%) were strikingly d

58 iology, diagnosis, imaging, and treatment of endocrine tumors of the pancreas.

59 3p was identified in 33% of 43 patients with endocrine tumors of the pancreas.

60 astrointestinal submucosa and the islet cell endocrine tumors of the pancreas.

61 alterations that override these controls in endocrine tumors often are not associated with oncogenes

62 Forty-two patients with advanced pancreatic endocrine tumors or carcinoid tumors were treated with r

63 objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients),

64 Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neop

65 Pancreatic endocrine tumors (PETs) have long fascinated clinicians

66 nomas as well as other functional pancreatic endocrine tumors (PETs) in whom the excess-hormone state

67 he pathogenesis of sporadic human pancreatic endocrine tumors (PETs).

68 In human adrenal endocrine tumors (pheochromocytoma), gallein attenuated

69 ine neoplasia type 1 (MEN1) develop multiple endocrine tumors, primarily affecting the parathyroid, p

70 Endocrine tumors such as aldosterone-producing adrenal a

71 l molecule Gbetagamma inhibition in treating endocrine tumors such as pheochromocytoma, in addition t

72 Endocrine tumors, such as parathyroid adenomas and pheoc

73 sent in both benign and malignant pancreatic endocrine tumors, suggesting that a MENIN gene mutation

74 in, a protein previously characterized as an endocrine tumor suppressor and transcriptional regulator

75 hromosome 3p25 may harbor a novel pancreatic endocrine tumor suppressor gene, and allelic loss of thi

76 NETs occur either sporadically or as part of endocrine tumor susceptibility syndromes such as multipl

77 s regimen appeared more active in pancreatic endocrine tumors than in carcinoid tumors.

78 Gastrinomas are rare gastrin-secreting endocrine tumors that usually arise in the duodenum or p

79 As in many endocrine tumors, there are no uniform definitive histol

80 Thirty-one sporadic pancreatic endocrine tumors were analyzed for mutation of MENIN by

81 Pancreatic endocrine tumors were found in all patients at surgery,

82 Twenty-nine sporadic and MEN1 pancreatic endocrine tumors were studied for loss of heterozygosity

83 inoid tumors and eight multifocal pancreatic endocrine tumors, were studied.

84 ine tumors include carcinoids and pancreatic endocrine tumors, which share a number of common feature

85 Patients with pancreatic endocrine tumors with liver metastases should undergo SR

86 activation of the Men1 in pancreas developed endocrine tumors with no exocrine tumor manifestation, r

87 ntinued inclusion and analysis of pancreatic endocrine tumors with small intestinal neuroendocrine tu